PURPOSE: Quality of life (QoL) has been increasingly emphasized in National Cancer Institute (NCI)-sponsored multisite clinical trials. Little is known about the outcomes of these trials in pediatric cancer. Objectives were to describe the proportion of Children's Oncology Group (COG) QoL studies that successfully accrued subjects and were analyzed, presented or published. METHODS: We conducted a survey to describe outcomes of COG QoL studies. We included studies that contained at least one QoL assessment and were closed to patient accrual at the time of survey dissemination. Respondents were the investigators most responsible for the QoL aim. RESULTS: Sixteen studies were included; response rate was 100%. Nine (56%) studies were embedded into a cancer treatment trial. Only 3 (19%) studies accrued their intended sample size. Seven (44%) studies were analyzed, 9 (56%) were presented, and 6 (38%) were published. CONCLUSIONS: NCI-sponsored pediatric QoL studies have high rates of failure to accrue. Many were not analyzed or disseminated. Using these data, strategies have been implemented to improve conduct in future trials. Monitoring of QoL studies is important to maximize the chances of study success.
PURPOSE: Quality of life (QoL) has been increasingly emphasized in National Cancer Institute (NCI)-sponsored multisite clinical trials. Little is known about the outcomes of these trials in pediatric cancer. Objectives were to describe the proportion of Children's Oncology Group (COG) QoL studies that successfully accrued subjects and were analyzed, presented or published. METHODS: We conducted a survey to describe outcomes of COG QoL studies. We included studies that contained at least one QoL assessment and were closed to patient accrual at the time of survey dissemination. Respondents were the investigators most responsible for the QoL aim. RESULTS: Sixteen studies were included; response rate was 100%. Nine (56%) studies were embedded into a cancer treatment trial. Only 3 (19%) studies accrued their intended sample size. Seven (44%) studies were analyzed, 9 (56%) were presented, and 6 (38%) were published. CONCLUSIONS: NCI-sponsored pediatric QoL studies have high rates of failure to accrue. Many were not analyzed or disseminated. Using these data, strategies have been implemented to improve conduct in future trials. Monitoring of QoL studies is important to maximize the chances of study success.
Authors: Sue P Heiney; Swann Arp Adams; Joan E Cunningham; Wendy McKenzie; Brook Harmon; James R Hebert; Mary Modayil Journal: Cancer Nurs Date: 2006 Jul-Aug Impact factor: 2.592
Authors: Oxana Palesh; Wendy Demark-Wahnefried; Karen Mustian; Lori Minasian; Julia Rowland; Lisa Sprod; Michelle Janelsins; Luke Peppone; Jeff Sloan; Karen Basen Engquist; Lee Jones; Diana Buist; Electra D Paskett Journal: Cancer Epidemiol Biomarkers Prev Date: 2011-04-18 Impact factor: 4.254
Authors: David Vanhoff; Tanya Hesser; Katherine Patterson Kelly; David Freyer; Susan Stork; Lillian Sung Journal: BMC Med Res Methodol Date: 2013-12-31 Impact factor: 4.615
Authors: Donna L Johnston; Rajaram Nagarajan; Mae Caparas; Fiona Schulte; Patricia Cullen; Richard Aplenc; Lillian Sung Journal: PLoS One Date: 2013-09-06 Impact factor: 3.240